Patent ID: 9125917
Filing Date: 2015-09-08
Classification: A61K,A61P

Abstract:
1. An implantable drug depot for reducing or treating pain, inflammation, and/or tissue transplant rejection in a patient in need of such treatment, the implantable drug depot comprising fluocinolone or a pharmaceutically acceptable salt thereof in an amount from about 0.5 wt. % to about 25 wt. % of the drug depot, and at least one biodegradable polymer having an inherent viscosity of 0.6 dL/g to 0.8 dL/g comprising poly(lactide-co-glycolide), D-lactide, D,L-lactide, L-lactide, D,L-lactide-caprolactone, or D,L-lactide-glycolide-ε-caprolactone or a combination thereof, wherein the drug depot is implanted by injection and has a surface that releases a burst dose of the fluocinolone or the pharmaceutically acceptable salt thereof in an amount of 0.001 μg to 5 μg within 24 hours at a site beneath the skin, and the depot releases an effective amount of the fluocinolone or a pharmaceutically acceptable salt thereof over a period of at least fifty days, and the drug depot has a modulus of elasticity from about 2×10 5 dynes/cm 2 to about 5×10 5 dynes/cm 2 , and a particle size from about 10 to about 200 micrometers, and the drug depot further comprises mPEG.